## Patrick Behrendt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/359085/publications.pdf

Version: 2024-02-01

22 877 13 22 g-index

23 23 23 23 971

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut, 2016, 65, 1733-1743.	12.1	145
2	The impact of hepatitis E in the liver transplant setting. Journal of Hepatology, 2014, 61, 1418-1429.	3.7	115
3	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2132-2139.	3.2	75
4	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. Clinical Infectious Diseases, 2020, 71, 1204-1211.	5 <b>.</b> 8	74
5	HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. Lancet Infectious Diseases, The, 2014, 14, 678-679.	9.1	73
6	Robust hepatitis E virus infection and transcriptional response in human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1731-1741.	7.1	67
7	The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo. Antiviral Research, 2018, 157, 151-158.	4.1	62
8	Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. Journal of Hepatology, 2017, 67, 480-489.	3.7	51
9	Hepatitis E virus replication and interferon responses in human placental cells. Hepatology Communications, 2018, 2, 173-187.	4.3	40
10	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. Journal of Hepatology, 2020, 73, 696-699.	3.7	39
11	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. Journal of Hepatology, 2019, 71, 673-684.	3.7	25
12	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 2019, 70, 593-602.	3.7	20
13	Hepatitis E virus <scp>ORF</scp> 1 induces proliferative and functional Tâ€cell responses in patients with ongoing and resolved hepatitis E. Liver International, 2018, 38, 266-277.	3.9	18
14	Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. Journal of Hepatology, 2022, 76, 46-52.	3.7	17
15	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	7.3	16
16	Hepatitis E virus is highly resistant to alcohol-based disinfectants. Journal of Hepatology, 2022, 76, 1062-1069.	3.7	11
17	Exacerbation of hepatitis E virus infection during anti-TNFα treatment. Joint Bone Spine, 2017, 84, 217-219.	1.6	9
18	Tâ€cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide. Liver International, 2022, 42, 1770-1771.	3.9	7

#	Article	IF	CITATIONS
19	Diet-induced obesity, exogenous leptin-, and MADB106 tumor cell challenge affect tissue leukocyte distribution and serum levels of cytokines in F344 rats. Endocrine, 2010, 38, 104-112.	2.3	5
20	Significant compartmentâ€specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. Liver International, 2021, 41, 1815-1823.	3.9	4
21	Stability and transmission of hepatitis CÂvirus in different anesthetic agents. American Journal of Infection Control, 2013, 41, 942-943.	2.3	3
22	Influence of alcohol consumption on blood coagulation in rotational thromboelastometry (ROTEM): an in-vivo study. Korean Journal of Anesthesiology, 2020, 73, 334-341.	2.5	1